HT
TVRD

HAP Trading’s Tvardi Therapeutics TVRD Stock Holding History

HAP Trading’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-425
Closed -$269K – 2692
2021
Q1 		$332K Buy
+425
New +$291K 0.02% 612
2018
Q4 		– Sell
-299
Closed -$258K – 1333
2018
Q3 		$258K Buy
+299
New +$216K 0.02% 408

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAP Trading's TVRD Position: Q2 2021 in Review

HAP Trading sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 425 shares — an estimated $269K sold.

HAP Trading first reported a position in TVRD in Q3 2018 and held it in 2 quarters. The position peaked at $332K in Q1 2021. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • HAP Trading reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HAP Trading sold 425 Tvardi Therapeutics shares in Q2 2021, an estimated $269K.
  • HAP Trading first reported a position in Tvardi Therapeutics in Q3 2018 and held it in 2 quarters.
  • HAP Trading's Tvardi Therapeutics position peaked at $332K in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on HAP Trading's 13F filing for Q2 2021, filed 11 Aug 2021.